openPR Logo
Press release

Tapentadol Market: Set for Rapid Growth and Trend by 2025

02-13-2018 07:34 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Persistence Market Research

/ PR Agency: Persistence Market Research
Tapentadol Market: Set for Rapid Growth and Trend by 2025

Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of December 2010 and by the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK on the fourth of February 2011.

Request Report for TOC @ https://www.persistencemarketresearch.com/toc/20656

Tapentadol has been recognized as a step three analgesic on the World Health Organization (WHO) pain ladder. Tapentadol is utilized for the treatment of moderate to severe pain for chronic and acute musculoskeletal pain. Tapentadol is available in the U.S. in extended release formulations as Nucynta ER from Janssen Pharmaceuticals. Nucynta contains the (R,R) stereoisomer, which is a weak isomer in terms of opioid activity.

Tapentadol is often used to ease pain which cannot be managed with other types of analgesics. Tapentadol formulation is provided in 100 mg (red/orange), 75 mg (orange) and 50 mg (yellow) tablets to be used once every five hours as needed to control pain. In addition, tapentadol can be used for controlling the pain of diabetic neuropathy when round the clock analgesic is required.

Furthermore, tapentadol can be used to treat chronic depression, although it is not approved for this treatment. However, tapentadol is known to have adverse side effects. Tapentadol may impair cognitive and physical abilities and should not be used when operating heavy machinery, especially during initial treatment. Dizziness, nausea, constipation and central nervous system (CNS) sedation are common side effects of tapentadol. Tapentadol can increase the risk of seizure and should be administered carefully to epileptic patients.

The growth in the analgesic market is expected to increase the consumption of tapentadol. In addition, rising demand for over the counter painkillers in emerging economies of Asia Pacific is expected to boost demand for tapentadol. However, government regulations, availability of substitutes and adverse effects of tapentadol could hamper the growth of the market.The market is dominated by large pharmaceutical companies with established brands.

Request to Sample of Report- https://www.persistencemarketresearch.com/samples/20656

Some of the key players operating in this market are Johnson & Johnson Pharmaceutical Research & Development, L.L.C (U.S.), IPCA Laboratories Ltd (India), Lupin Laboratories Ltd (India), Ranbaxy Laboratories Ltd.(India), Aristo Pharmaceuticals Pvt Ltd (India), Cadila Pharmaceuticals Ltd (India), Tirupati Medicare Ltd (India) and Manus Aktteva Biopharma LLP (India) among others. Companies are investing in research and development to develop new grades of Tapentadol. In addition, companies are using strategic acquisitions and mergers to remain competitive in market and increasing their presence in emerging economies of Asia Pacific and Latin America.

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web:https://www.persistencemarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tapentadol Market: Set for Rapid Growth and Trend by 2025 here

News-ID: 940752 • Views:

More Releases from Persistence Market Research

Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Reaching USD 82.4 Billion by 2031
Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Re …
The Artificial Intelligence as a Service (AIaaS) market has emerged as one of the most transformative segments in the global technology ecosystem. By providing AI capabilities on a subscription or pay-per-use model, AIaaS allows organizations to deploy advanced AI functionalities without the need for significant in-house infrastructure. This model has democratized access to AI, enabling small and medium-sized enterprises to leverage predictive analytics, natural language processing, and machine learning tools
Server Operating System Market Anticipated to Witness Robust Growth, Reaching USD 34.5 Billion by 2031
Server Operating System Market Anticipated to Witness Robust Growth, Reaching US …
The server operating system market is witnessing robust growth, driven by the rapid expansion of data centers and the surging adoption of cloud technologies across enterprises worldwide. Server operating systems form the backbone of modern IT infrastructure, enabling organizations to efficiently manage hardware resources, deploy applications, and maintain high levels of system reliability and security. As businesses increasingly migrate to cloud environments and data-intensive operations grow, demand for powerful, scalable,
Manufacturing Operations Management Software Industry Anticipated to Witness Rapid Growth, Reaching USD 69.8 Billion by 2032
Manufacturing Operations Management Software Industry Anticipated to Witness Rap …
The Manufacturing Operations Management (MOM) software market is rapidly emerging as a cornerstone of digital transformation in the manufacturing sector. As industries increasingly adopt Industry 4.0 practices, the need for advanced solutions that integrate production planning, real-time monitoring, quality control, and process optimization has surged. MOM software enables manufacturers to streamline operations, reduce production downtime, and improve overall efficiency, making it an indispensable tool across automotive, pharmaceutical, aerospace, and consumer
G.Fast Chipset Market Forecast to Expand with Absolute $ Growth of USD 28.3 Billion by 2032
G.Fast Chipset Market Forecast to Expand with Absolute $ Growth of USD 28.3 Bill …
The G.Fast chipset market has emerged as a pivotal segment within the broadband and telecommunication infrastructure industry, driven by the rising demand for high-speed internet and improved last-mile connectivity solutions. With advancements in fiber-to-the-distribution-point (FTTdp) networks, the adoption of G.Fast chipsets has witnessed unprecedented growth across residential, commercial, and industrial applications. These chipsets enable ultra-fast broadband speeds over existing copper lines, bridging the performance gap between fiber and legacy infrastructures,

All 5 Releases


More Releases for Tapentadol

Tapentadol Market to Witness Huge Growth by 2031 - Johnson & Johnson Services, I …
DataM Intelligence has published a new research report on "Tapentadol Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/tapentadol-market The
The Tapentadol Market to witness an innovative overhaul between 2017 - 2025
Tapentadol Market Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of
The next 10 years to see the Tapentadol Market making green strides
Tapentadol Market Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of
Tapentadol Market Grows With Changing Consumer Preferences & New Opportunities
Market: Overview Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of
Tapentadol Market High Growth Rate by 2025
Global Tapentadol Market: Snapshot The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is
Middle East Tapentadol Market Forecast to 2025
Tapentadol is an opioid analgesic, indicated for severe pain management, on a daily or around the clock need for treatment and long-term opioid treatment, for which alternative treatment options are inadequate. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is widely used for management of acute, chronic, and cancer related pain among patients and is available legally on prescription. Nucynta ER is the first and